Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

NCT02943473 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Poor accrual and risk/benefit ratio.

Conditions

High Risk Smoldering Multiple Myeloma

Interventions

DRUG: Ibrutinib

Sponsor

Icahn School of Medicine at Mount Sinai

Collaborators

[object Object]